First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Flaig, T. W.; Friedlander, T. W.; Milowsky, M. I.; Srinivas, S.; Petrylak, D. P.; Merchan, J. R.; Bilen, M. A.; Carret, A. S.; Yuan, N.; Sasse, C.; Hoimes, C. J. |
| Abstract Title: | First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC) |
| Meeting Title: | 2020 Swiss Oncology and Hematology Congress (SOHC) |
| Journal Title: | Swiss Medical Weekly |
| Volume: | 150 |
| Issue: | Suppl. 247 |
| Meeting Dates: | 2020 Nov 18-21 |
| Meeting Location: | Virtual |
| ISSN: | 1424-7860 |
| Publisher: | E M H Swiss Medical Publishers Ltd |
| Date Published: | 2020-11-17 |
| Start Page: | 26 S |
| End Page: | 27 S |
| Language: | English |
| ACCESSION: | WOS:000592781900062 |
| PROVIDER: | wos |
| PUBMED: | 33200807 |
| DOI: | 10.4414/smw.2020.20411 |
| Notes: | Meeting Abstract: P42 -- Source: Wos |
